Business Areas
Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.
Sales
Sales :2021 ,2022 ,2023
2021 0.8
2022 0.9
2023 1.2

Unit : KRW trillion

  • 2023 Acquired AVEO, a US-based cancer drug company
  • 2022 Applied for global Phase lll clinical trial for Tigulixostat(new dug for gout) with the US
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in ChinaSucceeded in phase II clinical trial of the new gout drug in the US
  • 2019 Established the Global Innovation Center in Boston, US
  • 2017 Merged with
    LG Life Sciences
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1984 Established Pharmaceuticals
    business division
  • 1961 Obtained the drug manufacturing permit
Division
Primary Care Division Primary Care Division
Specialty Care Division Specialty Care Division
Aesthetic Division Aesthetic Division
Go to the related products ▶
VISION

Toward a World-Class Innovative Drug Developer

  • 5 or more innovative new drugs by 2030
  • Enhanced the quality of new drug pipeline
  • Invest over USD 250mil in annual R&D
  • Strengthening of Open innovation
  • Diabetes, metabolic diseases, cancer, autoimmune diseases
  • Expand new drug pipelines in clinical development stage
  • Expand new drug pipelines in clinical development stage :2023 ,2030
    2023 12EA
    2030 20EA

    Explore Research Preclinical Clinical

  • Accelerate clinical developments and business growth worldwide
  • New tasks for global clinical development
  • Continued growth of AVEO's oncology business in the US
LG Chem Life Science Pipeline

As of April 2024

  • Aesthetic
  • Cell Therapy
  • Diabetes & Metabolism
  • Oncology & Immunology
  • Vaccine
  1. Preclinical (4)
    • LR19023

      Oncology
      LR19023
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR22011

      Oncology
      LR22011
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR19128

      Oncology
      LR19128
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner Avactar Life sciences

      Affimer® Technology

    • LR20008

      HA filler
      LR20008
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication HA filler
      Modality HA
      Target HA
      Partner -
  2. Phase I (10)
    • LR19129

      CUE-102
      Oncology
      LR19129
      해당 프로젝트 팝업
      Molecule CUE-102
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target WT-1
      Partner Cue Biopharma
    • LR19127

      CUE-101
      Oncology
      LR19127
      해당 프로젝트 팝업
      Molecule CUE-101
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication HNSCC
      Modality Biologics
      Target HPV
      Partner Cue Biopharma
    • LR19125

      PDC*Lung
      Oncology
      LR19125
      해당 프로젝트 팝업
      Molecule PDC*Lung
      Stage Phase 1
      (by Partner)
      Location summary Europe
      Indication NSCLC
      Modality Cell therapy
      Target Cancer vaccine
      Partner PDC*line Pharma
    • LR20011

      GEN-001
      Oncology
      LR20011
      해당 프로젝트 팝업
      Molecule GEN-001
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Solid tumor
      Modality Microbiome
      Target Microbiome
      Partner Genome & Company
    • AV-380

      AV-380
      Oncology
      AV-380
      해당 프로젝트 팝업
      Molecule AV-380
      Stage Phase 1
      Location summary USA
      Indication Cachexia
      Modality Biologics
      Target anti-GDF15 IgG1 mAb
      Partner -
    • AV-203

      Oncology
      AV-203
      해당 프로젝트 팝업
      Molecule AV-203
      Stage Phase 1
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target Anti-ERBB3
      IgG1 mAb
      Partner -
    • LR19155

      Oncology
      LR19155
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner -
    • LR19123

      LC542019
      Diabetes
      LR19123
      해당 프로젝트 팝업
      Molecule LC542019
      Stage Phase 1
      Location summary USA
      Indication Diabetes
      Modality NCE
      Target GPR120
      Partner -
    • LR19018

      LG203003
      NASH
      LR19018
      해당 프로젝트 팝업
      Molecule LG203003
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target DGAT-2
      Partner -
    • LR20062

      aP 6 in 1 Vaccine
      LR20062
      해당 프로젝트 팝업
      Molecule aP vaccine
      Stage Phase 1
      Indication aP vaccine
      Modality Vaccine
      Target aP vaccine
      Partner -

      Diphtheria, Tetanus, Pertussis,

      Polio, Hib, HebB ​

  3. Phase II (4)
    • LR19021

      LB54640
      Genetic Obesity
      LR19021
      해당 프로젝트 팝업
      Molecule LB54640
      Stage Phase 2
      Location summary USA
      Indication Genetic Obesity
      Modality NCE
      Target MC4R
      Partner -
    • LR19114

      6 in 1 Vaccine
      LR19114
      해당 프로젝트 팝업
      Molecule 6 in 1 Vaccine
      Stage Phase 2
      Indication 6 in 1 Vaccine
      Modality Vaccine
      Target 6 in 1 Vaccine
      Partner -

      Diphtheriae (D), Bordetella pertussis (wP),

      Clostridium tetani (T), Hepatitis B (HepB)

      Haemophilus influenzae type b(Hib)

      Vaccine-Associated Paralytic Poliomyelitis(IPV)

    • LR19019

      Zectivimod
      Atopic Dermititis
      LR19019
      해당 프로젝트 팝업
      Molecule Zectivimod
      Synonyms:LC510255
      Stage Phase 2
      (by Partner)
      Location summary China
      Indication Ulcerative colitis
      Atopic dermatitis
      Modality NCE
      Target S1P1
      Partner TransThera
      (License-out)

      License-out, China

    • LR19024

      LG34053
      Osteoarthritis
      LR19024
      해당 프로젝트 팝업
      Molecule LG34053
      Stage Phase 1b/2
      Location summary Republic of Korea
      Indication Osteoarthritis
      Modality NCE
      Target Undisclosed
      Partner -
  4. Phase III (4)
  5. NDA (2)
    • LR20024

      Y-solution, MDR
      HA Filler
      LR20024
      해당 프로젝트 팝업
      Molecule Y-solution, MDR
      Stage NDA
      Location summary Europe
      Indication HA filler
      Modality HA
      Target HA
      Partner -
    • LR19094

      Y-solution, China
      HA Filler
      LR19094
      해당 프로젝트 팝업
      Molecule Y-solution, China
      Stage NDA
      Location summary China
      Indication HA filler
      Modality HA
      Target HA
      Partner -
Image Download 다운로드
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo / Zemimet SR Tab. / Zemidapa Zemiglo / Zemimet SR Tab. / Zemidapa
Eucept Eucept
YVOIRE YVOIRE
Press Releases
LG Chem Initiates Phase 3 Clinical Trial for Head and Neck Cancer Drug 2024.01.17
LG Chem Exports the Technology of LB54640, a Novel Rare Obesity Drug, to a U.S. company Rhythm Pharmaceuticals 2024.01.05
LG Chem Exports the Technology of LB54640, a Novel Rare Obesity Drug, to a U.S. company Rhythm Pharmaceuticals 2024.01.05
more
Video
Select Opening of a Global Innovation Center Opening of a Global Innovation Center